MaxCyte, Inc. (LON:MXCT – Get Free Report) shares hit a new 52-week low on Thursday . The company traded as low as GBX 210.36 ($2.72) and last traded at GBX 226.90 ($2.94), with a volume of 64798 shares trading hands. The stock had previously closed at GBX 230 ($2.98).
MaxCyte Trading Down 2.7 %
The company has a quick ratio of 14.38, a current ratio of 9.81 and a debt-to-equity ratio of 8.59. The firm has a market capitalization of £290.41 million, a P/E ratio of -8.06 and a beta of 1.13. The firm’s 50-day simple moving average is GBX 305.56 and its 200-day simple moving average is GBX 304.30.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Read More
- Five stocks we like better than MaxCyte
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 03/24 – 03/28
- How Technical Indicators Can Help You Find Oversold Stocks
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- What is the S&P 500 and How It is Distinct from Other Indexes
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
